Stereotaxis (STXS) Q3 2026 earnings review
Stereotaxis robot sales double, but catheter shortages hurt cash
Stereotaxis, a maker of surgical robots for heart and blood vessel procedures, doubled its equipment sales from last quarter while supply shortages held back its disposable catheter business. Total revenue rose 20% from a year ago to $8.9 million as robot and screen shipments hit $3.0 million, but recurring catheter and service revenue missed its $7 million target at $5.9 million. Chief executive David Fischel said catheter shortages left $1.9 million of hospital orders unshipped at quarter-end.
| Total revenue | $8.9M +20% from a year ago (plan implied ~$10M) |
|---|---|
| Recurring revenue | $5.9M +6% from a year ago (missed ~$7M plan) |
| Gross margin | 45% down 11 percentage points from a year ago |
| Cash-flow breakeven outlook | Pushed out within the next year (was first half of 2027) |
⚖️ Verdict: 🔴 Bearish
The story got worse because catheter supply limits, lower gross margins, and higher costs from the Robocath acquisition forced the company to take on expensive convertible debt and push back its breakeven goal. Cash dropped to $4 million before Stereotaxis raised $12 million upfront in 10% convertible notes, while the new $8 million quarterly expense plan sits 21% above the pre-acquisition pace by our math. The good news: hospital orders for disposable catheters exceeded shipments, and new GenesisX and Synchrony systems met the equipment sales target.
The question now is whether the third-quarter recurring revenue shortfall is a temporary factory bottleneck or signs of deeper procedure losses as hospitals leave older Johnson & Johnson catheters. If the contract manufacturer clears the $1.9 million order backlog, recurring revenue should jump and lift gross margins; if shortages persist, elevated cash burn will eat into the new debt. Fourth-quarter recurring revenue and gross margin will tell.
🐂 Bull Case
New Robot and Room Systems Doubled Equipment Sales
Stereotaxis makes robotic equipment that guides catheters through blood vessels and heart chambers. Chief executive David Fischel wants to shift the business toward robots and operating room screens that hospitals can install without rebuilding their rooms. Equipment revenue rose 60% from a year ago and doubled from last quarter to $3.0 million, matching the company's plan.
Sales came from "partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US", Fischel said. What to watch: whether equipment revenue holds near $3 million in the fourth quarter, which will show if Synchrony and GenesisX orders can replace the older system backlog.
Hospital Demand for Disposable Catheters Exceeded Shipments
The main growth plan is selling proprietary MAGiC disposable catheters, which are thin tubes doctors use once per heart procedure and then replace. Shipments of these new robot-guided catheters grew fast this quarter, and hospitals ordered far more than the company could deliver.
"We entered the fourth quarter with a backlog of approximately $1.9 million in disposable orders we did not convert to revenue because of supply constraints," Fischel said. By our math, shipping those orders would have lifted recurring revenue to $7.8 million, beating the $7.0 million target. What to watch: how much of that $1.9 million order backlog converts into fourth-quarter sales once manufacturing catches up.
🐻 Bear Case
Catheter Shortages Caused a Recurring Revenue Miss
Stereotaxis relies on recurring revenue from disposable catheters, service, and accessories to build a steady business as hospitals stop using older Johnson & Johnson tubes. Three months ago, management forecast about $7 million in third-quarter recurring revenue and $8 million for the fourth quarter.
Actual recurring revenue reached only $5.9 million, missing the target by 15% and falling 4% from the second quarter. Fischel said new catheter sales were "countered by general pressure on procedures due to supply shortages". In the outlook section, the surgical robotics company dropped its dollar targets and predicted only "growing recurring revenue and more consistent capital sales in the coming quarters".
This setback matters because hospitals cannot perform procedures when catheters are out of stock, so unshipped orders can turn into lost operations. What to watch: fourth-quarter recurring revenue against the earlier $8 million target, which will show if the single supplier can clear the bottleneck.
High-Cost Debt Replaces Thin Cash and Pushes Out Breakeven
Closing the purchase of Robocath, a French vascular robotics maker, drained the balance sheet just as operating losses grew. Cash fell to $4.0 million at the end of September after $6.5 million in third-quarter cash outflow. Alongside the results, the medical device maker signed a deal for up to $24 million in convertible notes to refill its bank account.
- Third-quarter cash burn: $2.6 million for core operations and $3.9 million for Robocath acquisition payments
- New convertible debt: $12 million upfront and $12 million tied to regulatory milestones, carrying 10% annual interest
- Dilution math: diluted shares rose 11.5% from a year ago to 102.5 million, and converting all $24 million of notes at $1.21 per share would add 19.8 million shares by our math
Stereotaxis said the financing "bridges the Company to profitability" and gives a "pathway to cash-flow profitability within the next year", pushing back its earlier target of the first half of 2027. What to watch: quarterly cash burn in the fourth quarter, because reaching breakeven within a year requires cutting the core cash drain to zero.
Low Factory Volume and Robocath Costs Hurt Margins
Profitability moved backward in the third quarter because factory costs rose and the Robocath acquisition added new overhead. Total gross margin dropped 10.6 percentage points from a year ago to 44.3%, as the cost of making products climbed from 45.1% of revenue to 55.7%. Both recurring gross margin at 58.9% and equipment gross margin at 15.2% "remain impacted by fixed overhead allocated over low production volume", the company said.
Research and development spending also rose by 5.4 percentage points of revenue to 39.5%. Operating expenses excluding one-offs and non-cash items jumped 38% to $9.1 million on "one-time acquisition transaction costs and the absorption of Robocath operating expense", and management plans to spend about $8 million per quarter going forward. What to watch: recurring gross margin next quarter, which must rebound toward 66% if new catheter volume absorbs factory overhead.
Risks this quarter didn't answer
Several operational figures and clinical milestones from prior quarters were not disclosed in the third-quarter press release and await the conference call or quarterly filing.
- Proprietary catheter sales: disclosed as over $1 million last quarter, but the release gave no dollar figure or growth rate for the third quarter.
- Catheter factory output: no monthly production rate was given against the year-end goal of 500 MAGiC catheters per month.
- GenesisX installations and X-ray compatibility: partial revenue was booked on the first US robot, but formal X-ray compatibility and the European hospital install remain open.
- Pulsed-field ablation trials: no update on first-in-human procedures combining MAGiC with pulsed-field energy, which was planned before year-end.
👓 Other Themes
Robocath Acquisition and Canon Deal Expand the Platform
Stereotaxis closed its purchase of Robocath and announced an operating room collaboration with imaging maker Canon during the quarter. The deal expands the product line beyond heart rhythm procedures into wider blood vessel surgery, while adding $25.5 million of goodwill and lifting total contingent earnout liabilities on the balance sheet by $10.2 million from year-end to $19.8 million.
💲 Other KPIs
Inventories rose for a third straight quarter, climbing 38.7% from $9.57 million at the end of 2025 and 6.0% from $12.52 million in the second quarter. Stocking new robot systems and parts has tied up cash all year, running against management's earlier goal for working capital to generate cash in 2026.
Total deferred revenue — cash customers have paid upfront for service contracts and equipment not yet delivered — fell 28.4% from $8.15 million a year ago and 7.7% from $6.31 million last quarter. By our math, the balance combines $5.42 million of current and $0.41 million of long-term deferred revenue.
Accrued legal liabilities rose from $4.32 million at the end of 2025 and $6.32 million in the second quarter to $9.98 million. The surgical robotics group records an identical $9.98 million insurance receivable on the asset side of the balance sheet, so the net effect on equity is zero if the insurer pays.
🔮 Guidance
New. Stereotaxis expects quarterly operating expenses excluding non-cash charges and one-offs "to approximate $8 million per quarter going forward". By our math, that is down 12.1% from $9.1 million in the third quarter once one-time deal fees drop out, but up 21.2% from the $6.6 million quarterly pace before the Robocath purchase.
Cut. The device maker now sees a "pathway to cash-flow profitability within the next year", moving the goal back from the first half of 2027. By our math, covering $8 million of quarterly operating costs at this quarter's 44.3% gross margin would require $18.1 million in quarterly sales, double the third quarter's $8.9 million.
Cut. Management expects "growing recurring revenue and more consistent capital sales in the coming quarters", replacing the specific fourth-quarter targets of $8 million in recurring revenue and $3 million in system sales issued last quarter. By our math, across the two recent quarters with dollar targets, total revenue missed the middle of the plan by an average of 7.4%.
❓ Key Questions
What was proprietary robotic catheter revenue in the third quarter?
Last quarter management disclosed that MAGiC and MAGiC Sweep catheter sales passed $1 million and forecast $1 million of quarterly additions. The third-quarter release gave no dollar figure, making it hard to separate new catheter growth from legacy Johnson & Johnson attrition.
Will monthly MAGiC production reach 500 catheters by year-end?
Stereotaxis ended the quarter with $1.9 million in unshipped disposable catheter orders because of supply shortages. Investors need the current monthly output rate from contract manufacturer Osypka to judge when the backlog will clear.
Which regulatory milestones unlock the second $12 million debt draw?
The new $24 million convertible note provides $12 million upfront and holds back $12 million until the company meets undisclosed regulatory milestones. Knowing which product clearances trigger that funding is vital for tracking cash runway.
How much revenue and cost did Robocath add in Q3?
Closing the Robocath acquisition lifted quarterly operating expenses excluding one-offs from $6.6 million to a planned $8.0 million run-rate. Management did not disclose how much revenue or gross margin loss the French unit contributed.